Compare Southern Copper Corp (SCCO) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southern Copper Corp vs Travere Therapeutics Inc. Common Stock — how do they compare? Southern Copper Corp trades at $198 (market cap $169.44B), while Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B). The key difference: Southern Copper Corp is far larger — about 33.8× Travere Therapeutics Inc. Common Stock's market cap, and Southern Copper Corp pays a 2.19% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Southern Copper Corp for 62 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SCCO | TVTX | |
|---|---|---|
Market Cap | $169.44B | $5.02B |
Volume | 888,492 | 2,060,842 |
Sector | Basic Materials | Health |
52-Week High | $219.70 | $67.52 |
52-Week Low | $120.02 | $26.79 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $170.74B | $5.15B |
Dividend Yield | 2.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southern Copper (SCCO) trades at $207.42, down 0.61% on the day, with strong fundamental performance including 35.9% net margins and 50.1% ROE. The stock shows bullish technical signals with support at $207 and resistance at $210, while consistently beating earnings estimates in recent quarters. Revenue growth accelerated to $13.4B in 2025 with net income reaching $4.3B, supported by operational cash flow of $4.8B.
Despite premium valuations (P/E 31.1, P/S 11.2), SCCO's world-class assets and $10.2B Mexican project pipeline support long-term growth. However, analyst consensus remains cautious with only 10% buy ratings and a $165.60 price target, 20% below current levels. Key risks include copper price volatility and the stock's valuation premium relative to peers.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
